We are live on ! Find out more
IPHA

Innate Pharma
IPHA

10 hedge funds and large institutions have $49M invested in Innate Pharma in 2020 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 5 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.48% less ownership

Funds ownership: 9.82% → 9.34% (-0.48%)

1% less capital invested

Capital invested by funds: $49.7M → $49M (-$636K)

17% less funds holding

Funds holding: 12 → 10 (-2)

25% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 4

80% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 5

Holders
10
Holders Change
-2
Holders Change %
-16.67%
% of All Funds
0.22%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
1
Reduced
5
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$2.02M
2
Morgan Stanley
Morgan Stanley
New York
+$22.2K
3
Deutsche Bank
Deutsche Bank
Germany
+$674

Top Sellers

Rank Fund Capital Flow
1
RCMNY
Rubric Capital Management (New York)
New York
-$2.82M
2
MS
Maven Securities
Jersey
-$836K
3
EC
EcoR1 Capital
California
-$538K
4
Wellington Management Group
Wellington Management Group
Massachusetts
-$133K
5
OAM
Oxford Asset Management
United Kingdom
-$100K
Name Holding Trade Value Shares
Change 		Change in
Stake
EC
1
EcoR1 Capital
California
$29.8M -$538K -79,786 -2%
Wellington Management Group
2
Wellington Management Group
Massachusetts
$8.91M -$133K -19,663 -1%
RCMNY
3
Rubric Capital Management (New York)
New York
$6.22M -$2.82M -418,327 -31%
Adage Capital Partners
4
Adage Capital Partners
Massachusetts
$3.34M +$2.02M +300,000 +150%
Millennium Management
5
Millennium Management
New York
$485K -$10.7K -1,585 -2%
OAM
6
Oxford Asset Management
United Kingdom
$196K -$100K -14,829 -34%
Morgan Stanley
7
Morgan Stanley
New York
$22K +$22.2K +3,300 New
Osaic Holdings
8
Osaic Holdings
Arizona
$13K +$13.5K +2,000 New
SPIA
9
Steward Partners Investment Advisory
New York
$7K – – –
Deutsche Bank
10
Deutsche Bank
Germany
$1K +$674 +100 New
MS
11
Maven Securities
Jersey
– -$836K -130,000 Closed
OMC
12
Old Mission Capital
Illinois
– -$84K -13,038 Closed
FIA
13
FNY Investment Advisers
New York
– -$11K -1,795 Closed
TRCT
14
Tower Research Capital (TRC)
New York
– -$6K -937 Closed

IPHA Hedge Fund Activity: Q1 2020 in Review

10 of the 4,539 institutional investors tracked by Wall St. Rank reported a position in Innate Pharma (IPHA) for Q1 2020, worth a combined $49M — down 1.3% from $49.7M a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of IPHA and 3 opened new positions — a net loss of 1 holder — while 5 trimmed existing stakes and 1 added.

The largest buyer was Adage Capital Partners, adding an estimated $2.02M. The largest seller was Rubric Capital Management (New York), cutting an estimated $2.82M.

  • 10 institutional investors held Innate Pharma (IPHA) as of Q1 2020, down from 12 in Q4 2019.
  • Funds reported $49M of Innate Pharma stock for Q1 2020, down 1.3% quarter-over-quarter.
  • 3 funds opened new Innate Pharma positions in Q1 2020 and 4 closed out, a net change of -1 holder.
  • The largest Innate Pharma buyer in Q1 2020 was Adage Capital Partners, an estimated $2.02M added.
  • The largest Innate Pharma seller in Q1 2020 was Rubric Capital Management (New York), an estimated $2.82M sold.

Based on aggregated 13F filings for Q1 2020.